The criteria for potential treatment beyond MMR/MSI testing and POLE/POLD1 are unclear, but data from the NICHE trial suggest that immunotherapy may have the potential for complete response in dMMR tumours and at least partial response in some pMMR tumours with higher levels of CD8+ T cells.65 The gene discussed is CD8A; the disease is neoplasm.